UBS: Yunnan Botanee Bio-Technology - Q1 2026 Results Beat Expectations
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
UBS initiates coverage of Yunnan Botanee Bio-Technology (300957) with an initial earnings review, noting the company comfortably surpassed expectations during the first quarter of 2026. Botanee reported Q1 revenue of RMB 1.12 billion, representing 18% year-over-year growth. Recurring net profit surged 95% annually to RMB 41 million, signaling a strong recovery trajectory.
This robust quarterly performance follows a challenging fiscal year 2025, where total revenue declined 6.6% to RMB 5.43 billion. The core Winona brand experienced a 10% revenue contraction in 2025, though notable bright spots emerged from sub-brands Winona Baby and Aoxmed, which posted impressive growth of 17% and 115% respectively. Gross margins remained healthy, improving 0.7 percentage points to 74.5% for the full year, before dipping to 73.3% in Q1 2026 due to channel and product mix dynamics.
Operating leverage provided some relief, as Q1 recurring net margin expanded 1.4 percentage points annually. The market responded enthusiastically to the earnings beat, with shares surging approximately 11% on April 27. The company has not issued formal forward guidance. Applying a discounted cash flow methodology, UBS assigns a Neutral rating with a 12-month target price of RMB 46.00, citing potential risks related to brand concentration and competitive dynamics.